MX2012002830A - Formulacion estable de hialuronano/esteroide. - Google Patents
Formulacion estable de hialuronano/esteroide.Info
- Publication number
- MX2012002830A MX2012002830A MX2012002830A MX2012002830A MX2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A
- Authority
- MX
- Mexico
- Prior art keywords
- stable
- composition
- steroid formulation
- stable hyaluronan
- hyaluronan
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920002674 hyaluronan Polymers 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title 1
- 229940099552 hyaluronan Drugs 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 abstract 2
- 229960004221 triamcinolone hexacetonide Drugs 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/556,869 US8273725B2 (en) | 2009-09-10 | 2009-09-10 | Stable hyaluronan/steroid formulation |
| PCT/US2010/044975 WO2011031402A1 (en) | 2009-09-10 | 2010-08-10 | Stable hyaluronan/steroid formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002830A true MX2012002830A (es) | 2012-04-10 |
Family
ID=43648224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002830A MX2012002830A (es) | 2009-09-10 | 2010-08-10 | Formulacion estable de hialuronano/esteroide. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8273725B2 (en11) |
| EP (2) | EP2475251B1 (en11) |
| JP (2) | JP6121717B2 (en11) |
| CN (1) | CN102573468B (en11) |
| AR (1) | AR078281A1 (en11) |
| BR (1) | BR112012005423B1 (en11) |
| MX (1) | MX2012002830A (en11) |
| WO (1) | WO2011031402A1 (en11) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007070617A1 (en) | 2005-12-14 | 2007-06-21 | Anika Therapeutics, Inc. | Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
| SG178146A1 (en) | 2009-07-30 | 2012-03-29 | Carbylan Biosurgery Inc | Modified hyaluronic acid polymer compositions and related methods |
| DK2699274T3 (en) | 2011-04-20 | 2015-06-15 | Carbylan Therapeutics Inc | In situ gelling formations |
| TWI424007B (zh) | 2011-12-22 | 2014-01-21 | Ind Tech Res Inst | 使膠體交聯的方法與藉由此方法形成之經交聯的膠體 |
| AU2014205213B2 (en) * | 2013-01-11 | 2017-09-21 | Carbylan Therapeutics, Inc. | Stabilized compositions comprising hyaluronic acid |
| IT201600075246A1 (it) * | 2016-07-19 | 2018-01-19 | Jointherapeutics S R L | Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi. |
| CN106983733A (zh) * | 2017-03-08 | 2017-07-28 | 江苏富泽药业有限公司 | 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用 |
| KR20190038368A (ko) | 2017-09-29 | 2019-04-08 | 주식회사 엘지화학 | 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법 |
| CN118021719A (zh) * | 2022-11-11 | 2024-05-14 | 北京华视诺维医疗科技有限公司 | 一种曲安奈德组合物及其制备方法 |
| WO2025068242A1 (en) * | 2023-09-25 | 2025-04-03 | Hyamedix | Dexamethasone delivery system |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE51421B1 (en) * | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| SE442820B (sv) | 1984-06-08 | 1986-02-03 | Pharmacia Ab | Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut |
| US4582865A (en) | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| SE8501022L (sv) | 1985-03-01 | 1986-09-02 | Pharmacia Ab | Format alster och forfarande for dess framstellning |
| US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| IT1198449B (it) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| US4866050A (en) * | 1988-04-27 | 1989-09-12 | Ben Amoz Daniel | Ultrasonic transdermal application of steroid compositions |
| IT1219587B (it) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
| US5356883A (en) * | 1989-08-01 | 1994-10-18 | Research Foundation Of State University Of N.Y. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US5234914A (en) * | 1991-06-11 | 1993-08-10 | Patent Biopharmaceutics, Inc. | Methods of treating hemorrhoids and anorecial disease |
| US5207983A (en) * | 1992-01-29 | 1993-05-04 | Sterling Winthrop Inc. | Method of terminal steam sterilization |
| IT1260154B (it) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn) |
| US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
| US5621093A (en) * | 1995-06-06 | 1997-04-15 | Anika Research, Inc. | Steam-sterilizing solid hyaluronic acid |
| US5827937A (en) | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
| TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
| SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| US6066292A (en) * | 1997-12-19 | 2000-05-23 | Bayer Corporation | Sterilization process for pharmaceutical suspensions |
| US6521223B1 (en) * | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US6548081B2 (en) | 2000-07-28 | 2003-04-15 | Anika Therapeutics, Inc. | Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| AU2002223896B9 (en) * | 2000-11-24 | 2007-04-26 | Breath Limited | Sterilisation of pharmaceuticals |
| WO2003002159A1 (en) * | 2001-06-29 | 2003-01-09 | Biovitrum Ab | Process for bulk autoclaving |
| WO2003089476A1 (en) | 2002-04-17 | 2003-10-30 | Genzyme Corporation | Cross-linked hyaluronate compounds |
| US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| WO2005066215A1 (en) | 2003-12-30 | 2005-07-21 | Genzyme Corporation | Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use |
| US7879817B2 (en) | 2004-01-07 | 2011-02-01 | Seikagaku Corporation | Hyaluronic acid derivative and drug containing the same |
| US20060094700A1 (en) * | 2004-11-02 | 2006-05-04 | Allergan, Inc. | Heat sterilization of a steroid in the presence of phosphate |
| CA2633957A1 (en) | 2005-12-14 | 2007-06-21 | Anika Therapeutics, Inc. | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
| CN101677957A (zh) | 2007-02-05 | 2010-03-24 | 卡比兰生物外科公司 | 用于递送生物活性试剂的聚合物制剂 |
| FR2918276B1 (fr) | 2007-07-02 | 2010-01-22 | Anteis Sa | "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires" |
| US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
| EP2238163A1 (en) | 2008-01-31 | 2010-10-13 | Sofradim Production | Preparation of terminally-sterilized collagen that is soluble at neutral ph |
-
2009
- 2009-09-10 US US12/556,869 patent/US8273725B2/en active Active
-
2010
- 2010-08-10 MX MX2012002830A patent/MX2012002830A/es active IP Right Grant
- 2010-08-10 EP EP10815804.9A patent/EP2475251B1/en active Active
- 2010-08-10 JP JP2012528801A patent/JP6121717B2/ja active Active
- 2010-08-10 EP EP19186507.0A patent/EP3622820A1/en active Pending
- 2010-08-10 CN CN201080043915.0A patent/CN102573468B/zh active Active
- 2010-08-10 WO PCT/US2010/044975 patent/WO2011031402A1/en active Application Filing
- 2010-08-10 BR BR112012005423-6A patent/BR112012005423B1/pt active IP Right Grant
- 2010-09-08 AR ARP100103295A patent/AR078281A1/es unknown
-
2012
- 2012-08-23 US US13/593,026 patent/US8680073B2/en active Active
-
2015
- 2015-07-10 JP JP2015138590A patent/JP2015172095A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012005423B1 (pt) | 2022-09-13 |
| JP2015172095A (ja) | 2015-10-01 |
| EP2475251A4 (en) | 2012-10-24 |
| CN102573468B (zh) | 2015-05-20 |
| WO2011031402A1 (en) | 2011-03-17 |
| JP2013504570A (ja) | 2013-02-07 |
| EP2475251A1 (en) | 2012-07-18 |
| US8680073B2 (en) | 2014-03-25 |
| BR112012005423A2 (pt) | 2017-07-04 |
| US20120316131A1 (en) | 2012-12-13 |
| JP6121717B2 (ja) | 2017-04-26 |
| CN102573468A (zh) | 2012-07-11 |
| US20110059918A1 (en) | 2011-03-10 |
| EP2475251B1 (en) | 2019-07-17 |
| EP3622820A1 (en) | 2020-03-18 |
| AR078281A1 (es) | 2011-10-26 |
| US8273725B2 (en) | 2012-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012002830A (es) | Formulacion estable de hialuronano/esteroide. | |
| IN2012DN01216A (en11) | ||
| BR112012017136A2 (pt) | Composição farmacêutica compreendendo 3-beta- hidróxi-5-alfa-pregnan-20-ona com propriedades de armazenamento e solubidade aperfeiçoadas. | |
| SG10201901089TA (en) | Novel lipids and compositions for the delivery of therapeutics | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| PH12012502016A1 (en) | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | |
| NZ600759A (en) | Use of an oleogel containing triterpene for healing wounds | |
| TN2011000471A1 (en) | Pharmaceutical composition presenting anti-inflammatory properties | |
| BR112012033391A2 (pt) | kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova. | |
| BR112014016550A8 (pt) | formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma | |
| IL211946A (en) | Annotated (2-Hydroxy-2-Phenyl-1-Pyrrolidine-1-Illmethyl-Ethyl) -Carbamic Acid Phenyl Ester | |
| BR112014032239A2 (pt) | inibidores da família de mir-15 de micro-rnas | |
| BR112013006362A2 (pt) | uso de compostos profármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para reduzir a pressão intraocular, composição farmacêutica e artigo de fabricação | |
| NZ630471A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| BR112014016661A2 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
| BR112017011476A2 (pt) | composição baseada em aminoácidos para recuperação de fibroelastina em tecidos conjuntivos dérmicos e uso | |
| UA105920C2 (uk) | ПОХІДНІ СПОЛУК СТЕРОЇДАЛ[3,2-с]ПІРАЗОЛУ З ГЛЮКОКОРТИКОЇДНОЮ АКТИВНІСТЮ | |
| EP2145623A4 (en) | PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR ACCELERATING THE PROCESS OF WOUND HEALING AND OTHER SURFACE INJURIES | |
| BR112012022683A8 (pt) | Agente de cura para resinas epóxi, formulação de resina epóxi à base de água, uso das formulações de resina epóxi à base de água, composição de tinta ou de revestimento, produtos curados, e, método para preparar um agente de cura | |
| CA2805805C (en) | Bendamustine anionic-catioinic cyclopolysaccharide compositions | |
| WO2009120700A3 (en) | Inhibition of dcps | |
| BR112012000522A2 (pt) | método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso da relação il10/ifnt como um biomarcador, kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, método ex-vivo para predizer se um paciente é ou não suscetível a sobreviver mais tempo após administração de uma composição imunogênica | |
| MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| MX2014001065A (es) | Formulaciones de (trimetoxifenilamino) pirimidilino nuevas. | |
| GB201101170D0 (en) | Restorative materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |